Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Laekna, Inc.

來凱醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2105)

VOLUNTARY ANNOUNCEMENT

SUCCESSFUL COMPLETION OF PHASE I SAD STUDY OF LAE103 IN OVERWEIGHT OR OBESE PARTICIPANTS

This announcement is made by Laekna, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board (the "**Board**") of directors of the Company (the "**Directors**") is pleased to announce that the Group has successfully completed the Phase I single ascending dose study (the "**SAD Study**") of LAE103 in overweight or obese participants. The SAD Study was a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE103, administered subcutaneously, in overweight or obese participants in Australia.

A single subcutaneous dose of LAE103 was well tolerated. No serious adverse events and no discontinuations due to adverse events were reported. Obvious target engagement and expected pharmacodynamic biomarker changes were observed. Single doses of LAE103 showed a dose proportional PK profile and clear PK/PD correlation, supporting once-monthly subcutaneous dosing regimen, and demonstrating excellent drug developabilities.

ABOUT LAE103

LAE103 is an ActRIIB selective antibody. The Group is actively accelerating the clinical study of this drug candidate as novel therapies for sarcopenic obesity and other muscle related diseases.

RISK WARNING

LAE103 MAY ULTIMATELY NOT BE SUCCESSFULLY DEVELOPED AND COMMERCIALIZED. THE COMPANY'S SHAREHOLDERS AND POTENTIAL INVESTORS ARE REMINDED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.

By Order of the Board
Laekna, Inc.
Dr. LU Chris Xiangyang
Chairman

Hong Kong, November 9, 2026

As at the date of this announcement, the Board comprises Dr. LU Chris Xiangyang, Ms. XIE Ling and Dr. GU Xiang-Ju Justin as executive Directors; Dr. WANG David Guowei and Mr. SUN Yuan as non-executive Directors; and Dr. YIN Xudong, Dr. LI Min and Mr. ZHOU Jian as independent non-executive Directors.